Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials

Journal of Affective Disorders

Volumn 200, Issue , 2016, Pages 235-242

  Salagre, Estela ^a,b   Fernandes, Brisa S ^a,c   Dodd, Seetal ^a,e   Brownstein, Daniel J ^d   Berk, Michael ^a,e  

^a DEAKIN UNIVERSITY   (Australia)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Depression; Depressive symptoms; Inflammation; Meta analysis; Randomized controlled trial; Statins; Systematic review; Treatment

Indexed keywords

ATORVASTATIN; CITALOPRAM; FLUOXETINE; MEVINOLIN; PLACEBO; SIMVASTATIN; ANTIDEPRESSANT AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ABDOMINAL PAIN; ADD ON THERAPY; ARTICLE; BACKACHE; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DECREASED APPETITE; DEPRESSION; DRUG INDUCED HEADACHE; FLU LIKE SYNDROME; FOLLOW UP; HAMILTON DEPRESSION RATING SCALE; HUMAN; INCREASED APPETITE; INSOMNIA; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINITIS; VOMITING; DOUBLE BLIND PROCEDURE; MAJOR DEPRESSION; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ATORVASTATIN CALCIUM; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FLUOXETINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84968779745     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2016.04.047     Document Type: Article

References (53)

1. S.H. Abbasi, P. Mohammadinejad, N. Shahmansouri, A. Salehiomran, A.A. Beglar, A. Zeinoddini, S. Forghani, and S. Akhondzadeh Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial J. Affect. Disord. 183 2015 149 155
2. J. Andrews, G. Guyatt, A.D. Oxman, P. Alderson, P. Dahm, Y. Falck-Ytter, M. Nasser, J. Meerpohl, P.N. Post, R. Kunz, J. Brozek, G. Vist, D. Rind, E.A. Akl, and H.J. Schunemann GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations J. Clin. Epidemiol. 66 2013 719 725
3. M. Berk, and A.A. Nierenberg Three paths to drug discovery in psychiatry Am. J. Psychiatry 172 2015 412 414
4. J. Bowden, J.F. Tierney, A.J. Copas, and S. Burdett Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics BMC Med. Res. Methodol. 11 2011 41
5. C.M. Carlsson, K. Papcke-Benson, M. Carnes, P.E. McBride, and J.H. Stein Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults Drugs Aging 19 2002 793 805
6. C.S. Chuang, T.Y. Yang, C.H. Muo, H.L. Su, F.C. Sung, and C.H. Kao Hyperlipidemia, statin use and the risk of developing depression: a nationwide retrospective cohort study Gen. Hosp. Psychiatry 36 2014 497 501
7. S. Dodd, B.S. Fernandes, and O.M. Dean Future directions for pharmacotherapies for treatment-resistant bipolar disorder Curr. Neuropharmacol. 13 2015 656 662
8. S. Duval, and R. Tweedie Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis Biometrics 56 2000 455 463
9. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
10. L. Feng, C.H. Tan, R.A. Merchant, and T.P. Ng Association between depressive symptoms and use of HMG-CoA reductase inhibitors (statins), corticosteroids and histamine H(2) receptor antagonists in community-dwelling older persons: cross-sectional analysis of a population-based cohort Drugs Aging 25 2008 795 805
11. B.S. Fernandes, J. Steiner, H.G. Bernstein, S. Dodd, J.A. Pasco, O.M. Dean, P. Nardin, C.A. Goncalves, and M. Berk C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications Mol. Psychiatry 2015
12. A. Ghanizadeh, and A. Hedayati Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial Depress. Anxiety 30 2013 1084 1088
13. J. Glaus, C.L. Vandeleur, A.M. Lasserre, M.P. Strippoli, E. Castelao, M. Gholam-Rezaee, G. Waeber, J.M. Aubry, P. Vollenweider, and M. Preisig Aspirin and statin use and the subsequent development of depression in men and women: results from a longitudinal population-based study J. Affect. Disord. 182 2015 126 131
14. C.J. Glueck, M. Tieger, R. Kunkel, T. Tracy, J. Speirs, P. Streicher, and E. Illig Improvement in symptoms of depression and in an index of life stressors accompany treatment of severe hypertriglyceridemia Biol. Psychiatry 34 1993 240 252
15. B.A. Golomb, M.H. Criqui, H.L. White, and J.E. Dimsdale The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes Control. Clin. Trials 25 2004 178 202
16. A. Gougol, N. Zareh-Mohammadi, S. Raheb, M. Farokhnia, S. Salimi, N. Iranpour, H. Yekehtaz, and S. Akhondzadeh Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: a double-blind placebo-controlled trial J. Psychopharmacol. 29 2015 575 581
17. F. Guillot, P. Misslin, and M. Lemaire Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods J. Cardiovasc. Pharmacol. 21 1993 339 346
18. R. Haapakoski, K.P. Ebmeier, H. Alenius, and M. Kivimaki Innate and adaptive immunity in the development of depression: an update on current knowledge and technological advances Prog. Neuropsychopharmacol. Biol. Psychiatry 66 2015 63 72
19. M. Haghighi, S. Khodakarami, L. Jahangard, M. Ahmadpanah, H. Bajoghli, E. Holsboer-Trachsler, and S. Brand In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder J. Psychiatr. Res. 58 2014 109 114
20. R.W. Harrison, and C.H. Ashton Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers Br. J. Clin. Pharmacol. 37 1994 231 236
21. Higgins, J.P.T.; G.S.e.; 2011 [updated March 2011]. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration.
22. R.I. Holt, D.I. Phillips, K.A. Jameson, C. Cooper, E.M. Dennison, and R.C. Peveler The relationship between depression, anxiety and cardiovascular disease: findings from the Hertfordshire Cohort Study J. Affect. Disord. 150 2013 84 90
23. M.T. Hyyppa, E. Kronholm, A. Virtanen, A. Leino, and A. Jula Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial Psychoneuroendocrinology 28 2003 181 194
24. F.S. Kilic, Y. Ozatik, B. Kaygisiz, C. Baydemir, and K. Erol Acute antidepressant and anxiolytic effects of simvastatin and its mechanisms in rats Neurosciences 17 2012 39 43
25. S.W. Kim, K.Y. Bae, J.M. Kim, I.S. Shin, Y.J. Hong, Y. Ahn, M.H. Jeong, M. Berk, and J.S. Yoon The use of statins for the treatment of depression in patients with acute coronary syndrome Transl. Psychiatry 5 2015 e620
26. M. Law Having too much evidence (depression, suicide, and low serum cholesterol) BMJ 313 1996 651 652 (Clinical research ed.)
27. A.F. Macedo, F.C. Taylor, J.P. Casas, A. Adler, D. Prieto-Merino, and S. Ebrahim Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 12 2014 51
28. Marina Marcus, M.T.Y.; van Ommeren, Mark, Chisholm, Dan, Saxena, Shekhar, 2012. DEPRESSION: a Global Public Health Concern. World Health Organization 2012, Department of Mental Health and Substance Abuse
29. A.J. McFarland, S. Anoopkumar-Dukie, D.S. Arora, G.D. Grant, C.M. McDermott, A.V. Perkins, and A.K. Davey Molecular mechanisms underlying the effects of statins in the central nervous system Int. J. Mol. Sci. 15 2014 20607 20637
30. K. Morales, M. Wittink, C. Datto, S. DiFilippo, M. Cary, T. TenHave, and I.R. Katz Simvastatin causes changes in affective processes in elderly volunteers J. Am. Geriatr. Soc. 54 2006 70 76
31. M.F. Muldoon, S.D. Barger, C.M. Ryan, J.D. Flory, J.P. Lehoczky, K.A. Matthews, and S.B. Manuck Effects of lovastatin on cognitive function and psychological well-being Am. J. Med. 108 2000 538 546
32. A. O'Neil, L. Sanna, C. Redlich, K. Sanderson, F. Jacka, L.J. Williams, J.A. Pasco, and M. Berk The impact of statins on psychological wellbeing: a systematic review and meta-analysis BMC Med. 10 2012 154
33. A.E. O'Neil The role of depression in the primary prevention of cardiovascular disease Med. J. Aust. 197 2012 444 445
34. Organization, W.H.; 2007. Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Total Cardiovascular Risk. WHO Library Cataloguing-in-Publication Data.
35. T. Ormiston, O.M. Wolkowitz, V.I. Reus, and F. Manfredi Behavioral implications of lowering cholesterol levels: a double-blind pilot study Psychosomatics 44 2003 412 414
36. A.K. Parsaik, B. Singh, M.H. Murad, K. Singh, S.S. Mascarenhas, M.D. Williams, M.I. Lapid, J.W. Richardson, C.P. West, and T.A. Rummans Statins use and risk of depression: a systematic review and meta-analysis J. Affect. Disord. 160 2014 62 67
37. I. Rahman, K. Humphreys, A.M. Bennet, E. Ingelsson, N.L. Pedersen, and P.K. Magnusson Clinical depression, antidepressant use and risk of future cardiovascular disease Eur. J. Epidemiol. 28 2013 589 595
38. J.G. Rahola Somatic drugs for psychiatric diseases: aspirin or simvastatin for depression? Curr. Neuropharmacol. 10 2012 139 158
39. S.G. Raja, and G.D. Dreyfus Statins: much more than just a lipid-lowering therapy Indian Heart J. 56 2004 204 209
40. C. Redlich, M. Berk, L.J. Williams, J. Sundquist, K. Sundquist, and X. Li Statin use and risk of depression: a Swedish national cohort study BMC Psychiatry 14 2014 348
41. Z. Reiner, A.L. Catapano, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M.J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P.P. Filardi, G. Riccardi, R.F. Storey, and D. Wood ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur. Heart J. 32 2011 1769 1818
42. J.F. Rosenbaum, M. Fava, S.L. Hoog, R.C. Ascroft, and W.B. Krebs Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial Biol. Psychiatry 44 1998 77 87
43. N.C. Santanello, B.L. Barber, W.B. Applegate, J. Elam, C. Curtis, D.B. Hunninghake, and D.J. Gordon Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study J. Am. Geriatr. Soc. 45 1997 8 14
44. K.L. Soeken, and A. Sripusanapan Assessing publication bias in meta-analysis Nurs. Res. 52 2003 57 60
45. L. Stafford, and M. Berk The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J. Clin. Psychiatry 72 2011 1229 1235
46. R.A. Stewart, K.J. Sharples, F.M. North, D.B. Menkes, J. Baker, and J. Simes Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study investigators Arch. Intern. Med. 160 2000 3144 3152
47. W.J. Sun, L. Xu, W.M. Chan, T.H. Lam, and C.M. Schooling Are depressive symptoms associated with cardiovascular mortality among older Chinese: a cohort study of 64,000 people in Hong Kong? Am. J. Geriatr. Psychiatry 21 2013 1107 1115
48. Tonstad, S.; Gorbitz, C.; Ose, L.; Malt, U.F.; 1994. A comparison between lovastatin and pravastatin - effects on lipids, sleep and quality of life in primary hyperlipidemia. Tidsskrift for den Norske laegeforening:tidsskrift for praktisk medicin, ny raekke, vol. 114, pp. 2262-2264
49. J.M. Waloszek, M.L. Byrne, M.J. Woods, C.L. Nicholas, B. Bei, G. Murray, M. Raniti, N.B. Allen, and J. Trinder Early physiological markers of cardiovascular risk in community based adolescents with a depressive disorder J. Affect. Disord. 175 2015 403 410
50. G.L. Xiong, K. Prybol, S.H. Boyle, R. Hall, R.D. Streilein, D.C. Steffens, R. Krishnan, J.G. Rogers, C.M. O'Connor, and W. Jiang Inflammation markers and major depressive disorder in patients with chronic heart failure: results from the sertraline against depression and heart disease in chronic heart failure study Psychosom. Med. 77 2015 808 815
51. C.C. Yang, S.S. Jick, and H. Jick Lipid-lowering drugs and the risk of depression and suicidal behavior Arch. Intern. Med. 163 2003 1926 1932
52. H. You, W. Lu, S. Zhao, Z. Hu, and J. Zhang The relationship between statins and depression: a review of the literature Expert Opin. Pharmacother. 14 2013 1467 1476
53. Y. Young-Xu, K.A. Chan, J.K. Liao, S. Ravid, and C.M. Blatt Long-term statin use and psychological well-being J. Am. Coll. Cardiol. 42 2003 690 697